Physician profile
David Ostransky
NPI 1396710984
$107,429.30
in general payments reported to CMS, 2019-2025
18 companies · $13K in 2025
The $13K reported for 2025 was more than what 94% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36K · 2020: $8,497 · 2021: $18K · 2022: $4,520 · 2023: $20K · 2024: $7,523 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $28K · Food and Beverage: $4,549 · Consulting Fee: $3,815 · Travel and Lodging: $3,588 · Education: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $28,117.00 |
| Food and Beverage | $4,549.39 |
| Consulting Fee | $3,815.00 |
| Travel and Lodging | $3,588.35 |
| Education | $150.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $45,923.54 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $24,084.30 | 2019-2025 | Breztri, Tezspire, Airsupra |
| Jazz Pharmaceuticals INC. | $23,442.99 | 2021-2025 | |
| Avadel Cns Pharmaceuticals, LLC | $5,058.39 | 2025 | Lumryz |
| Inspire Medical Systems, INC. | $3,601.14 | 2021-2025 | Inspire |
| Genentech USA, INC. | $1,455.00 | 2021 | |
| Novartis Pharmaceuticals Corporation | $1,330.00 | 2019 | |
| Genentech, INC. | $1,000.00 | 2020 | |
| Glaxosmithkline, LLC. | $818.94 | 2019-2023 | Trelegy Ellipta, Nucala, Arexvy |
| Advanced Respiratory, INC | $169.58 | 2019-2020 | |
| Zoll Respicardia, INC. | $166.26 | 2020-2023 | Remede System |
| Insmed, INC. | $130.00 | 2019 | |
| Harmony Biosciences LLC | $89.56 | 2021-2024 | |
| Pulmonx Corporation | $80.80 | 2025 | Chartis Catheter, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| Regeneron Healthcare Solutions, INC. | $35.44 | 2024-2025 | Dupixent |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $23.70 | 2025 | Ohtuvayre |
| Arbor Pharmaceuticals, INC. | $19.66 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Ostransky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.